Sales & Marketing News | pharmaphorum

News

Gilead to buy liver disease specialist CymaBay for $4.3bn

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC),

News

Pfizer/BioNTech COVID jab to be sold privately in UK

People in Great Britain will be able to buy the latest Omicron-directed version of Pfizer/BioNTech’s COVID-19 vaccine from retail pharmacies, starting in March.

News

BioNTech adds CAR-T manufacturing with $250m Autolus deal

Germany’s BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therap

News

Roche gets first world okay for PNH drug crovalimab

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal ha

News

Real Chemistry grows in med comms with Avant buy

Life sciences communications agency Real Chemistry has more than doubled its medical team through the acquisition of Avant Healthcare.

News

GSK backs up its Blenrep rehab bid with survival data

GSK has revealed the data it hopes will allow a return to the US market for Blenrep, which was the first BCMA-targeting drug to launch there, but was withdrawn from sale after it fail

Gilead to buy liver disease specialist CymaBay for $4.3bn

Pfizer/BioNTech COVID jab to be sold privately in UK

BioNTech adds CAR-T manufacturing with $250m Autolus deal

Roche gets first world okay for PNH drug crovalimab

Real Chemistry grows in med comms with Avant buy

GSK backs up its Blenrep rehab bid with survival data

Making direct-to-patient work, with Matt Wadyka

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks